Biomedical · global
Can Vitamin B3 Open an Immune Vulnerability in Glioblastoma?
An early-stage clinical trial has added controlled-release niacin to standard treatment, with preliminary progression-free survival higher than historical controls; but before it can become a therapy, it still faces hurdles including small size, non-randomization, and safety monitoring.
The cruelty of glioblastoma lies not only in its rapid growth, but also in how often it pushes treatment back to the starting point: after surgery, radiation, and temozolomide chemotherapy, tumors still frequently recur. Now, a seemingly ordinary molecule is being put to a serious clinical test: whether niacin, a form of vitamin B3, can help the immune system see this brain cancer again.
A team associated with the University of Calgary in Canada is conducting a Phase I to II trial adding controlled-release niacin to standard care for patients with newly diagnosed glioblastoma. This is not the idea of routine vitamin supplementation, but the use of a high-dose formulation under medical monitoring; the trial is registered on ClinicalTrials.gov under the number NCT04677049.
The biological rationale for the study comes from the immune microenvironment. Glioblastoma can weaken immune cells, pushing cells that might otherwise attack the tumor into an inefficient state. According to the team’s previous animal research and current clinical design, niacin may allow these suppressed immune cells to recover some function, thereby producing an adjunctive effect alongside existing treatments.
An interim analysis published in the Journal of Neuro-Oncology showed that Phase I enrolled 15 patients, with doses gradually increased from 500 milligrams per day to 3000 milligrams per day; at 2500 milligrams per day, two dose-limiting toxicities occurred, including grade 3 thrombocytopenia and hyperbilirubinemia, so the recommended dose for the subsequent Phase II was set at 2000 milligrams per day. The most common side effect was flushing, mostly mild.
The efficacy signal comes from the Phase II interim analysis. The researchers had originally set a rule that if the 6-month progression-free survival rate failed to improve by at least 20 percentage points over historical controls, the trial would stop for insufficient benefit; among 24 evaluable patients, centrally reviewed imaging reported a 6-month progression-free survival rate of 82.3%, about 28 percentage points higher than the historical benchmark used by the study.
That number is enough to support continuing the trial, but it is still not enough to rewrite clinical standards. The data at this stage remain small, interim results referenced against historical controls, and cannot rule out bias from patient composition, timing of imaging interpretation, or other treatment factors; overall survival, the course after recurrence, and long-term safety also require complete follow-up. The team’s goal is to complete the final analysis after enrolling 48 patients, which may fall in late 2026 or early 2027.
The real message of this study, therefore, is not that “vitamins can treat brain cancer,” but that immune modulation may come not only from expensive and complex new drugs, but also from the repositioning of known molecules. For patients, any high-dose niacin should not be tried on their own; for the research community, the next step is to use more complete evidence, preferably with randomized controls, to determine whether this immune vulnerability can truly be opened.